Skip to main content
. 2012 Apr 19;7(4):e35130. doi: 10.1371/journal.pone.0035130

Figure 1. Inhibition of Sp regulated genes by MTM-SDK and MTM-SK in prostate cancer cells in vitro.

Figure 1

PC3 cells were treated with 100 nM of MTM-SDK, MTM-SK or vehicle (DMSO) for 24 h. A) Gene expression was measured by qRT-PCR. Data were normalized to B2M RNA level and are presented as percentage of expression compared to vehicle-treated cells (control). Data represent the mean ± SD from 3 independent experiments. B) Binding of Sp1 to the promoters of C-MYC and VEGF in control and drug treated cells was determined by ChIP using an anti-Sp1 specific antibody. DNA in input and immunoprecipitated fractions was quantified by qPCR with primers encompassing the Sp binding site in the gene promoters. Data (mean ± SD) from 3 independent experiments are expressed as percentage of input DNA in immunoprecipated fractions. *, P<0.01; **, P<0.001. C) Level of Sp1, Sp3 and Sp4 mRNA was determined by RT-PCR in PC3 cells incubated with 100 nM of MTM-SDK, MTM-SK or vehicle for 24 and 48 h. GAPDH was used as control. D) Protein level of Sp1, c-Myc, XIAP, and cyclin D1 was determined by immunoblotting in PC3 cells incubated with 100 nM of MTM-SDK, MTM-SK or vehicle for 24 and 48 h.